Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 27.3 %

NASDAQ BLPH opened at $0.04 on Monday. The company has a market cap of $489,200.00, a PE ratio of -0.05 and a beta of 0.71. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.10. The firm’s 50-day simple moving average is $0.04 and its two-hundred day simple moving average is $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.